Doença arterial obstrutiva periférica: que atenção temos dispensado à abordagem clínica dos pacientes?
Anaí Espinelli de Souza Durazzo; Cid José Sitrângulo Jr.; Calogero Presti; Erasmo Simão da Silva; Nelson De Luccia
Burns P, Lima E, Bradbury W. What constitutes best medical therapy for peripheral arterial disease?. Eur J Vasc Endovasc Surg.. 2002;24:1-12.
Hiatt WR. Pharmacologic therapy for peripheral arterial disease and claudication. J Vasc Surg.. 2002;36:1283-91.
Ouriel K. Peripheral arterial disease. Lancet. 2001;358:1257-64.
Management of Peripheral Arterial Disease (PAD) TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg.. 2000;31(1):3-9.
Rehring TF, Sandhoff BG, Stolcpart RS, Merenich JA, Hollis HW. Atherosclerotic risk factor control in patients with peripheral arterial disease. J Vasc Surg.. 2005;41:816-22.
Haffner M, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Eng J Med.. 1998;339:229-34.
Grundy SM, Cleeman JI, Merz NB. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol. 2004;44:720-32.
Joint British recommendations on prevention of coronary heart disease in clinical practice: British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, endorsed by the British Diabetic Association. Heart. 1998;80:S1-29.
III Diretrizes Brasileiras Sobre Dislipidemias e Diretriz de Prevenção da Aterosclerose do Departamento de Aterosclerose da Sociedade Brasileira de Cardiologia. Arq Bras Cardiol.. 2001;77:4-48.
Hirsch AT, Treat-Jacobson D, Lando HA, Hatsukamo DK. The role of tobacco cessation, antiplatelet and anti lipid-lowering therapies in the treatment of peripheral arterial disease. J Vasc Med.. 1996;2:243-51.
Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D. Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACLE) Study Investigators. Effects of atorvastatin on early recurrent ischemic events en coronary syndromes: a randomized controlled trial. JAMA. 2001;285:1758-60.
Burns P, Gough S, Bradbury AW. Management of peripheral arterial disease in primary care. BMJ. 2003;326:584-8.
The Heart Outcomes Prevention Evaluation Study Investigators: Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med.. 2000;342:145-53.
Donnelly R, Yeung JM. Management of intermittent claudication: the importance of secondary prevention. Eur J Vasc Endovasc Surg.. 2002;23:100-7.
Henke PK, Blackburn S, Proctor MC. Patients undergoing infrainguinal bypass to treat atherosclerotic vascular disease are underprescribed cardioprotective medications: Effect on graft patency, limb salvage, and mortality. J Vasc Surg.. 2004;39:357-65.
Mukherjee D, Lingham P, Chetcuti S, Grossman M. Missed opportunities to treat atherosclerosis in patients undergoing peripheral vascular interventions. Circulation. 2002;106:1909-12.
Cassar K, Belch JJ, Brittenden J. Are national cardiac guidelines being applied by vascular surgeons?. Eur J Vasc Endovasc Surg.. 2003;26:623-8.
Clark AL, Byrne JC, Nasser A, McGroarty E, Kennedy JA. Cholesterol in peripheral vascular disease-a suitable case for treatment?. QJM. 1999;92:219-22.
Bismuth J, Klitfod L, Sillesen H. The lack of cardiovascular risk factor management in patients with critical limb ischaemia. Eur J Vasc Endovasc Surg.. 2001;21:143-6.
Anand SS, Kundi A, Eikelboom J, Yusuf S. Low rates of preventive practices in patients with peripheral vascular disease. Can J Cardiol.. 1999;15:1259-63.
McDermott MM, Mehta S, Ahn H, Greenland P. Atherosclerotic risk factors are less intensively treated in patients with peripheral arterial disease than in patients with coronary artery disease. J Gen Intern Med.. 1997;12:209-15.
McDermott MM, Hahn EA, Greenland P. Atherosclerotic risk factor reduction in peripheral arterial disease: results of a national physician survey. J Gen Intern Med.. 2002;17:895-904.
Hirsch AT, Gotto AM Jr. Undertreatment of dyslipidemia in peripheral arterial disease and other high-risk populations: an opportunity for cardiovascular disease reduction. Vasc Med.. 2002;7:323-31.
Burns P, Lima E, Bradbury AW. Second best medical therapy. Eur J Vasc Endovasc Surg.. 2002;24:400-4.
Mukherjee D, Lingan P, Chetcuti S, Grossman PM, Moscucci M, Luciano AE, Eagle K. Missed opportunities to treat atherosclerosis in patients undergoing peripheral vascular interventions: insights from the University of Michigan Peripheral vascular disease quality improvement initiative (PVD-QI). Circulation. ;2002:1909-12.
Naylor AR. Does the modern concept of "best medical therapy" render carotid surgery obsolete?. Eur J Vasc Endovasc Surg.. 2004;28:457-61.
Leng GC, Price JF, Jepson RG. Cochrane review: lipid-lowering therapy in the treatment of lower limb atherosclerosis. Eur J Vasc Endovasc Surg.. 1998;16:5-6.
Pederson TR, Kjekshus J, Pyorala K. Effect of simvastatin on ischaemic signs and symptoms in the Scandinavian Simvastatin Survival (4S) study. Am J Cardiol.. 1998;81:333-5.
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22.
Durazzo AE, Machado FS, Ikeoka DT. Reduction of cardiovascular events after vascular surgery with atorvastatin: a randomized trial. J Vasc Surg.. 2004;39:967-76.
Murabito JM, D'Agostinho RB, Silbershatz H, Wilson PW. Intermittent claudication: a risk profile from the Framingham Heart Study. Circulation. 1997;96:44-9.
De Luccia N. Doença vascular e diabetes. J Vasc Br.. 2003;2:49-60.
McDaniel MD, Cronenwett JL. Basic data related to the natural history of intermittent claudication. Ann Vasc Surg.. 1989;3:273-7.
Wolosker N, Nakano L, Rosoky RA, Puech-Leão P. Evaluation of walking capacity over time in 500 patients with intermittent claudication who underwent clinical treatment. Arch Intern Med.. 2003;163:2296-300.
Antiplatelet Therapy in Peripheral Arterial Disease: Consensus Statement. Eur J Vasc Endovasc Surg.. 2003;26:1-16.
Collaborative overview of randomized trials of antiplatelet therapy: I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308:81-106.
Robless P, Mikhailidis DP, Stansby G. Systematic review of antiplatelet therapy for the prevention of myocardial infarction, stroke and vascular death in patients with peripheral arterial disease. Br J Surg.. 2001;88:787-800.
Collaborative overview of randomized trials of antiplatelet therapy: II: Maintenance of vascular graft or arterial patency by antiplatelet therapy. BMJ. 1994;308:159-68.
A randomized, blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet. 1996;348:1329-39.
Ameli FM, Stein M, Provan JL, Prosser R. The effect of postoperative smoking on femoropopliteal bypass graft. Ann Vasc Surg.. 1989;3:20-25.
Abordagem e Tratamento do Fumante: Consenso 2001. 2001.
Hobbs SD, Bradbury AW. Smoking cessation strategies in patients with peripheral arterial disease: an evidence-based approach. Eur J Vasc Endovasc Surg.. 2003;26:341-7.
IV Diretrizes Brasileiras de Hipertensão Arterial. Arq Bras Cardiol.. 2004;82(^sIV):7-22.